histamine has been researched along with Leukemia, Myeloid, Acute in 36 studies
Leukemia, Myeloid, Acute: Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Histamine has the potential to optimize cytokine-induced activation of T cells and natural killer cells; therefore, the addition of histamine to cytokine treatment may improve treatment efficacy." | 6.44 | Histamine dihydrochloride for the treatment of acute myeloid leukemia, malignant melanoma and renal cell carcinoma. ( Ho, AD; Perz, JB, 2008) |
| "Histamine has been well tolerated, and 21/22 CR patients have treated themselves at home throughout the trial." | 5.30 | Histamine and interleukin-2 in acute myelogenous leukemia. ( Brune, M; Carneskog, J; Celsing, F; Hellstrand, K; Kimby, E; Mellqvist, UH; Wallhult, E, 1997) |
| "Most patients with acute myeloid leukemia (AML) achieve complete remission (CR) after induction chemotherapy." | 2.46 | Immunotherapy with histamine dihydrochloride for the prevention of relapse in acute myeloid leukemia. ( Aurelius, J; Brune, M; Hellstrand, K; Martner, A; Söderholm, J; Thorén, FB, 2010) |
| "Histamine has the potential to optimize cytokine-induced activation of T cells and natural killer cells; therefore, the addition of histamine to cytokine treatment may improve treatment efficacy." | 2.44 | Histamine dihydrochloride for the treatment of acute myeloid leukemia, malignant melanoma and renal cell carcinoma. ( Ho, AD; Perz, JB, 2008) |
| "Histamine has been well tolerated, and 21/22 CR patients have treated themselves at home throughout the trial." | 1.30 | Histamine and interleukin-2 in acute myelogenous leukemia. ( Brune, M; Carneskog, J; Celsing, F; Hellstrand, K; Kimby, E; Mellqvist, UH; Wallhult, E, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (25.00) | 18.7374 |
| 1990's | 5 (13.89) | 18.2507 |
| 2000's | 6 (16.67) | 29.6817 |
| 2010's | 14 (38.89) | 24.3611 |
| 2020's | 2 (5.56) | 2.80 |
| Authors | Studies |
|---|---|
| Sahores, A | 1 |
| González, AR | 1 |
| Yaneff, A | 1 |
| May, M | 1 |
| Gómez, N | 1 |
| Monczor, F | 2 |
| Fernández, N | 2 |
| Davio, C | 2 |
| Shayo, C | 2 |
| Bernson, E | 3 |
| Hallner, A | 3 |
| Sander, FE | 3 |
| Nicklasson, M | 1 |
| Nilsson, MS | 2 |
| Christenson, K | 1 |
| Aydin, E | 1 |
| Liljeqvist, JÅ | 1 |
| Brune, M | 12 |
| Foà, R | 3 |
| Aurelius, J | 8 |
| Martner, A | 8 |
| Hellstrand, K | 14 |
| Thorén, FB | 10 |
| Nilsson, S | 1 |
| Rydström, A | 3 |
| Riise, RE | 1 |
| Kiffin, R | 2 |
| Riise, R | 1 |
| Anderson, H | 1 |
| Copsel, S | 1 |
| Cuapio, A | 1 |
| Post, M | 1 |
| Cerny-Reiterer, S | 1 |
| Gleixner, KV | 1 |
| Stefanzl, G | 1 |
| Basilio, J | 1 |
| Herndlhofer, S | 1 |
| Sperr, WR | 1 |
| Brons, NH | 1 |
| Casanova, E | 1 |
| Zimmer, J | 1 |
| Valent, P | 2 |
| Hofer, E | 1 |
| Romero, AI | 3 |
| Askarieh, G | 1 |
| Söderholm, J | 1 |
| Yang, LP | 2 |
| Perry, CM | 2 |
| Buyse, M | 2 |
| Squifflet, P | 2 |
| Lucchesi, KJ | 2 |
| Brune, ML | 2 |
| Castaigne, S | 2 |
| Rowe, JM | 2 |
| Berry, SM | 1 |
| Broglio, KR | 1 |
| Berry, DA | 1 |
| Michiels, S | 1 |
| Palmqvist, L | 1 |
| Hansson, M | 2 |
| Nelson, R | 1 |
| Perz, JB | 1 |
| Ho, AD | 1 |
| Sawutz, DG | 1 |
| Kalinyak, K | 1 |
| Whitsett, JA | 1 |
| Johnson, CL | 1 |
| van Gils, FC | 1 |
| Budel, LM | 1 |
| Burger, H | 1 |
| van Leen, RW | 1 |
| Löwenberg, B | 1 |
| Wagemaker, G | 1 |
| Makishima, M | 1 |
| Honma, Y | 1 |
| Hozumi, M | 1 |
| Sampi, K | 1 |
| Motoyoshi, K | 1 |
| Nagata, N | 1 |
| Hattori, M | 1 |
| Mellqvist, UH | 2 |
| Hermodsson, S | 1 |
| Wallhult, E | 1 |
| Carneskog, J | 1 |
| Kimby, E | 1 |
| Celsing, F | 1 |
| Naredi, P | 1 |
| Di Guglielmo, R | 1 |
| Catini, C | 1 |
| Gheri, G | 1 |
| Miliani, A | 1 |
| Bettelheim, P | 1 |
| Gespach, C | 3 |
| Marrec, N | 2 |
| Balitrand, N | 1 |
| Courillon-Mallet, A | 1 |
| Launay, JM | 1 |
| Cost, H | 1 |
| Abita, JP | 2 |
| Maurer, WM | 1 |
| Litos, M | 1 |
| Lutz, D | 1 |
| Rothenberg, ME | 1 |
| Caulfield, JP | 1 |
| Austen, KF | 1 |
| Hein, A | 1 |
| Edmiston, K | 1 |
| Newburger, PE | 1 |
| Stevens, RL | 1 |
| Timoshenko, LI | 1 |
| Klimenko, VI | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Open-Label, Multicenter, Effects of Remission Maintenance Therapy With Ceplene® , Given in Conjunction With Low-Dose Interleukin-2, on Immune Response and Minimal Residual Disease in Adult Patients With AML in First Complete Remission[NCT01347996] | Phase 4 | 84 participants (Actual) | Interventional | 2009-07-31 | Completed | ||
| Multi-Center, Randomized Open-Label Study to Evaluate the Safety and Efficacy of Immunotherapy With Subcutaneous Maxamine (Histamine Dihydrochloride) Plus Proleukin (Interleukin-2) Versus No Treatment (Standard of Care) in Patients With Acute Myeloid Leuk[NCT00003991] | Phase 3 | 360 participants (Anticipated) | Interventional | 1998-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
10 reviews available for histamine and Leukemia, Myeloid, Acute
| Article | Year |
|---|---|
Histamine H
Topics: Blood Cells; Histamine; Humans; Interleukin-2; Leukemia, Myeloid, Acute; Male; Receptors, Histamine | 2017 |
Histamine dihydrochloride and interleukin-2 in acute myeloid leukemia--background and results.
Topics: Clinical Trials as Topic; Disease-Free Survival; Drug Therapy, Combination; Histamine; Histamine Ago | 2009 |
Histamine dihydrochloride and low-dose interleukin-2 as post-consolidation immunotherapy in acute myeloid leukemia.
Topics: Dose-Response Relationship, Drug; Histamine; Humans; Immunotherapy; Interleukin-2; Killer Cells, Nat | 2009 |
Post-consolidation immunotherapy with histamine dihydrochloride and interleukin-2 in AML.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Histamine; Histamine Agonists; Humans; Imm | 2009 |
Immunotherapy with histamine dihydrochloride for the prevention of relapse in acute myeloid leukemia.
Topics: Antineoplastic Agents; Histamine; Humans; Immunotherapy; Interleukin-2; Leukemia, Myeloid, Acute; Mo | 2010 |
Histamine dihydrochloride: in the management of acute myeloid leukaemia.
Topics: Clinical Trials, Phase III as Topic; Drug Interactions; Female; Histamine; Humans; Immunotherapy; In | 2011 |
Spotlight on histamine dihydrochloride in acute myeloid leukaemia.
Topics: Aged; Antineoplastic Agents; Histamine; Histamine Agonists; Humans; Interleukin-2; Killer Cells, Nat | 2011 |
Addressing the incremental benefit of histamine dihydrochloride when added to interleukin-2 in treating acute myeloid leukemia: a Bayesian meta-analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Disease-Free Survival; Evidence | 2011 |
Histamine dihydrochloride for the treatment of acute myeloid leukemia, malignant melanoma and renal cell carcinoma.
Topics: Animals; Antineoplastic Agents; Antioxidants; Carcinoma, Renal Cell; Dose-Response Relationship, Dru | 2008 |
Histamine as an adjunct to immunotherapy.
Topics: Adjuvants, Immunologic; Animals; Antineoplastic Agents; Apoptosis; Cytotoxicity, Immunologic; Histam | 2002 |
10 trials available for histamine and Leukemia, Myeloid, Acute
| Article | Year |
|---|---|
Cytomegalovirus Serostatus Affects Autoreactive NK Cells and Outcomes of IL2-Based Immunotherapy in Acute Myeloid Leukemia.
Topics: Adolescent; Adult; Aged; Antibodies, Viral; Cytomegalovirus; Cytomegalovirus Infections; Female; His | 2018 |
Immunotherapy with HDC/IL-2 may be clinically efficacious in acute myeloid leukemia of normal karyotype.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Chromosome Aberrations; Data Analysis; Databases, Factua | 2020 |
NK cell expression of natural cytotoxicity receptors may determine relapse risk in older AML patients undergoing immunotherapy for remission maintenance.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CD56 Antigen; Female; Flow | 2015 |
Dynamics of cytotoxic T cell subsets during immunotherapy predicts outcome in acute myeloid leukemia.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Agents; Cells, Cultured; Female; Flow Cytometry | 2016 |
Maintenance therapy with histamine plus IL-2 induces a striking expansion of two CD56bright NK cell subpopulations in patients with acute myeloid leukemia and supports their activation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Histamine; Humans; Immunotherapy; Interleukin-2; Kil | 2016 |
Dynamics of myeloid cell populations during relapse-preventive immunotherapy in acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Cell Count; Female; Flow Cytometr | 2017 |
Spotlight on histamine dihydrochloride in acute myeloid leukaemia.
Topics: Aged; Antineoplastic Agents; Histamine; Histamine Agonists; Humans; Interleukin-2; Killer Cells, Nat | 2011 |
Assessment of the consistency and robustness of results from a multicenter trial of remission maintenance therapy for acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Disease-Free Survival; Fema | 2011 |
Leukemia-free survival as a surrogate end point for overall survival in the evaluation of maintenance therapy for patients with acute myeloid leukemia in complete remission.
Topics: Antineoplastic Agents; Biomarkers; Disease-Free Survival; Histamine; Humans; Immunotherapy; Interleu | 2011 |
Remission maintenance in acute myeloid leukemia: impact of functional histamine H2 receptors expressed by leukemic cells.
Topics: Apoptosis; Flow Cytometry; Follow-Up Studies; Histamine; Histamine Agonists; Humans; In Situ Hybridi | 2012 |
17 other studies available for histamine and Leukemia, Myeloid, Acute
| Article | Year |
|---|---|
Ceefourin-1, a MRP4/ABCC4 inhibitor, induces apoptosis in AML cells enhanced by histamine.
Topics: Animals; Apoptosis; ATP-Binding Cassette Transporters; Histamine; Humans; Leukemia, Myeloid, Acute; | 2023 |
Antitumor properties of histamine in vivo.
Topics: Animals; Antineoplastic Agents; Histamine; Humans; Leukemia, Myeloid, Acute; Mice; Myeloid Cells; Ne | 2011 |
Postconsolidation immunotherapy in leukaemia remission.
Topics: Histamine; Humans; Immunotherapy; Interleukin-2; Leukemia, Myeloid, Acute; Randomized Controlled Tri | 2006 |
Histamine H2 receptor desensitization in HL-60 human promyelocytic leukemia cells.
Topics: 1-Methyl-3-isobutylxanthine; Cell Differentiation; Cell Line; Cimetidine; Cyclic AMP; Dimaprit; Dino | 1984 |
Interleukin-3 (IL-3) receptors on rhesus monkey bone marrow cells: species specificity of human IL-3, binding characteristics, and lack of competition with GM-CSF.
Topics: Animals; Antigens, CD; Antigens, CD34; Binding, Competitive; Bone Marrow; Bone Marrow Cells; Cells, | 1994 |
Differentiation of human myeloblastic leukemia ML-1 cells into macrophages by staurosporine, an inhibitor of protein kinase activities.
Topics: Alkaloids; Cell Differentiation; Cytoplasmic Granules; Histamine; Humans; Leukemia, Myeloid, Acute; | 1993 |
Remission maintenance therapy with histamine and interleukin-2 in acute myelogenous leukaemia.
Topics: Adult; Aged; Female; Histamine; Humans; Immunotherapy; Interleukin-2; Killer Cells, Natural; Leukemi | 1996 |
NK cell-mediated killing of AML blasts: role of histamine, monocytes and reactive oxygen metabolites.
Topics: Catalase; CD56 Antigen; Cytotoxicity, Immunologic; Histamine; Histamine H2 Antagonists; Humans; Immu | 1996 |
Histamine and interleukin-2 in acute myelogenous leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Communication; Drug Synergism; Fem | 1997 |
[Cytochemistry of acid mucopolysaccharides and histamine in the human granulocytic line in normal and pathological conditions].
Topics: Bone Marrow; Bone Marrow Cells; Bone Marrow Examination; Glycosaminoglycans; Granulocytes; Histamine | 1975 |
[Radioimmunometric determination of histamine in myeloproliferative syndromes].
Topics: Animals; Antibodies, Monoclonal; Basophils; Histamine; Histamine Release; Humans; Interleukin-3; Leu | 1989 |
Relationship between 3H-histamine uptake and H2-receptors in the human promyelocytic leukemia cell line HL-60.
Topics: Antidepressive Agents, Tricyclic; Biological Transport; Cell Line; Cell Survival; Histamine; Histami | 1985 |
Histamine H2 receptor activity and histamine metabolism in human U-937 monocyte-like cells and human peripheral monocytes.
Topics: Adult; Cell Differentiation; Cell Line; Cyclic AMP; Histamine; Humans; Leukemia, Myeloid, Acute; Lym | 1986 |
Distinct histamine-induced cyclic AMP synthesis in acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Cyclic AMP; Female; Histamine; Histamine Antagonists; Humans | 1986 |
Biochemical and morphological characterization of basophilic leukocytes from two patients with myelogenous leukemia.
Topics: Arachidonic Acid; Arachidonic Acids; Basophils; Calcimycin; Cell Separation; Child, Preschool; Glyco | 1987 |
Pharmacological characterization of the histamine uptake system in HL-60 human promyelocytic leukemia cells.
Topics: Cell Line; Diphenhydramine; Histamine; Histamine Antagonists; Humans; Leukemia, Myeloid, Acute; Rece | 1986 |
[Several indices of histamine metabolism in patients with acute leukemia].
Topics: Acute Disease; Adolescent; Adult; Aged; Female; Hemorrhagic Disorders; Histamine; Humans; Leukemia; | 1971 |